If Brain Implants Become Mainstream, Here's How They Could Widen the Inequality Gap
The neurotech field is building the most powerful medical tools in history — and right now, nothing is stopping them from becoming the exclusive property of people who can already afford everything else.
There’s a version of the brain implant future that reads like a utopian brochure. Depression? Treated with a blueberry-sized chip in your skull. Paralysis? Bypassed entirely with a thought-to-cursor interface. Parkinson’s tremors? Quieted by a pacemaker wired to your basal ganglia. The technology is real, the clinical trials are enrolling, and the results so far are, in a few select cases, remarkable.
There’s another version of that future, though. One where the people who get access to those tools are exactly the people who already had better healthcare, more job security, higher salaries, and better educational outcomes. One where the gap between the cognitively augmented and the cognitively unaugmented stops being metaphorical and becomes literal, permanent, and measurable in electrode counts. That version is also on the table. And compared to the utopian one, it gets almost no attention.
I think about this a lot. The neurotech field is genuinely producing tools that could help millions of people who have failed every conventional treatment. That’s not hype — it’s verifiable and documented. But the same field is operating inside healthcare and economic systems that have a long, unambiguous track record of translating “available” into “available to some.” The question isn’t whether brain implant technology will arrive. It’s who gets to live inside it.
The price tag problem is already showing up
Start with the numbers, because they’re grounding.
Elon Musk has projected that high-volume Neuralink production could eventually bring device costs to $2,000-$3,000, while current early commercial procedures are estimated at around $10,500 in parts and labor — a figure that swells to approximately $40,000-$50,000 when insurer overhead is included. That’s the optimistic trajectory, and it assumes the kind of manufacturing scale that doesn’t yet exist.
Deep brain stimulation, the older and better-proven form of brain implant, has a clearer cost picture — and it’s not comfortable reading. Medicare does cover DBS for approved indications like Parkinson’s disease and essential tremor, provided patients meet strict eligibility criteria, including demonstrated limitations in daily activities and the ability to participate in postsurgical evaluations. But DBS for treatment-resistant depression isn’t yet approved by the FDA for commercial use, meaning insurers have no obligation to cover it. Currently, no specific insurance plans cover experimental neurostimulation technology, and future coverage will depend on FDA approval and demonstrated efficacy.
The pattern here is familiar to anyone who has watched a new medical technology enter the US healthcare system: 💡
Clinical trials cover costs for enrolled participants — but trial slots are scarce, selective, and geographically concentrated at academic medical centers
Early commercial access lands at premium pricing, mostly reachable through private insurance or out-of-pocket spending
Broader insurance coverage follows, sometimes by years or decades, and is often incomplete even then
Medicaid and lower-income populations typically arrive last, if at all
The BCI implant market was valued at roughly $351 million in 2025, with projections to reach $1.18 billion by 2035. That’s not a public health infrastructure story. That’s a premium medtech story, with premium medtech distribution patterns. And for every year a therapy remains outside standard insurance coverage, it accumulates a waiting list sorted by wealth.
China is, interestingly, trying something different. In March 2025, China’s National Medical Insurance Administration created a new insurance category specifically for BCI technology, directly addressing cost as one of the biggest barriers to adoption. Whether that coverage is substantive or nominal, it’s a structural choice the United States hasn’t made and shows no signs of making soon. 🔬
When “available” and “accessible” diverge
The access problem isn’t just about price. It’s about the entire infrastructure that connects a person to an experimental or newly approved medical device.
Consider geography. The TRANSCEND trial — Abbott’s pivotal study of deep brain stimulation for treatment-resistant depression — has 25 participating sites nationwide, including Mount Sinai in New York and Emory University in Atlanta. Those are world-class institutions. They are also in major metropolitan areas where neurological expertise, follow-up care, and the broader medical scaffolding those surgeries require already exist. Research has found that access to deep brain stimulation has historically marginalized remote communities, with recommendations emerging for telehealth-supported care as a partial solution. Partial is the operative word.
Then there’s the skill gap. Brain implant surgery requires neurosurgeons with highly specific training. The United States has roughly 3,000 neurosurgeons total, and the subset trained in stereotactic implant procedures is smaller still. Scaling up to even tens of thousands of patients annually, let alone hundreds of thousands, requires either a dramatic expansion of surgical training or the kind of robotic automation that Neuralink is building toward. Neither is fast. Neither is cheap. And in the interim, patients in rural areas, underserved communities, and regions without major academic medical centers will face access barriers that have nothing to do with their ability to pay. 📈
What does this look like in practice? A patient with severe treatment-resistant depression in rural Mississippi may have:
No neurologist within 100 miles, let alone a neurosurgeon with DBS experience
Medicaid coverage that won’t reach experimental devices for years after FDA approval
No trial eligibility because trial sites don’t exist near them
No advocacy infrastructure to navigate a complex experimental device process
No time off work for the multiple surgical and follow-up appointments an implant requires
Compare that to a patient in Boston or San Francisco with private insurance, proximity to a major academic medical center, and access to a knowledgeable psychiatrist who’s tracking emerging treatments. These two patients may have identical diagnoses, identical unmet needs, and radically different outcomes — not because of neuroscience, but because of zip codes and paychecks. That’s not a hypothetical future problem. It’s a current-day structural pattern that brain implants will slot directly into. 🧠
The enhancement problem: when treatment becomes advantage
So far, I’ve focused on the therapeutic side — devices designed to restore function to people who have lost it or never had it. That’s where the strongest moral case for brain implants lives, and that’s where the current clinical trials are focused.
But here’s the problem: the line between restoration and enhancement is not clean, and it gets blurrier as the technology matures. A frequently voiced concern in academic neuroethics is that neurotechnologies might be used to cognitively enhance only those who can afford them, unfairly increasing the divide in society. Elon Musk has been explicit that Neuralink’s long-term goal is not just medical restoration — it’s enhancement of healthy individuals. That’s a different conversation entirely.
And the workplace is already moving toward neurotech without waiting for implants. Brain-monitoring neurotechnology is already used in mining, finance, and other industries to measure brain waves and infer cognitive states, and the UK’s Information Commissioner’s Office predicts it will be common in workplaces by the end of the decade. The people whose employers are investing in that technology are not the same people whose employers are cutting benefits. The cognitive advantages of neurotech — enhanced focus, better stress management, faster learning through neurostimulation — will initially be available to workers at companies that can afford them.
That creates a particularly uncomfortable scenario where:
Knowledge workers at well-resourced companies get non-invasive neuroenhancement tools as workplace perks
Blue-collar workers get neuro-monitoring devices — their cognition tracked for fatigue and compliance, not enhanced for performance
The resulting productivity data flows upward to employers, not sideways to workers who generated it
Early adopters of enhancement implants gain cognitive advantages in hiring, promotion, and competitive performance that compound over careers
Neurodevice data obtained from workers could theoretically serve employers for purposes like promotion, hiring, or dismissal, something researchers at the University of Zurich have flagged specifically as a risk. The class dynamics of that scenario are not subtle. 💊
What the regulatory picture actually looks like
On November 12, 2025, UNESCO adopted its Recommendation on the Ethics of Neurotechnology — the first attempt at a global legal framework for the ethical development and use of neurotechnology, covering the entire lifecycle from design to disposal. The framework emphasizes human dignity, mental privacy, informed consent, and — importantly — equity. The UNESCO Recommendation explicitly states that neurotechnology should be used to reduce global health inequalities and improve health particularly in resource-limited settings.
That sounds good. The problem is that the Recommendation is non-binding. It carries no enforcement mechanism. A company that violates its principles faces no penalty. Its value is entirely aspirational — a normative framework hoping to be adopted by individual nations through their own legislative processes, which is a slow and inconsistent path.
The more enforceable action is happening at the state level in the United States, focused narrowly on neural data privacy. Colorado, California, and Montana have enacted laws treating neural data as sensitive personal information with specific protections. Colorado recognizes neural data as private property, granting residents the right to access and delete their neural data held by technology companies, and to prohibit its use for marketing purposes. That’s meaningful. But data privacy and access equity are different problems, and only one is getting serious legislative attention right now.
Chile remains the most notable national example. Chile became the first country in the world to amend its constitution to protect brain rights, including mental privacy, free will, and non-discrimination in citizens’ access to neurotechnology, with a goal of giving personal brain data the same status as an organ — not for sale, not for trafficking, not for manipulation. That’s a significantly more ambitious legal framework than anything the United States or EU has passed. But Chile’s neurotech industry is also not where the dominant BCI companies are operating. 🌍
What the global policy picture actually shows:
The most ambitious equity frameworks are nonbinding international guidance documents
The most enforceable regulations cover data privacy, not access or pricing
The nations with the most neurotech commercial activity (US, Europe, China) are taking different and incompatible approaches
The countries with the least existing healthcare infrastructure have essentially no neurotech policy at all
What a different path might look like
I want to be honest that this isn’t a solved problem with obvious policy answers. The history of medical technology does include cases where costs came down and access broadened — HIV antivirals, cochlear implants, and certain cancer therapies all eventually reached populations that couldn’t have afforded them at launch. The optimists point to this history and argue that brain implants will follow the same curve. They might be right.
But those historical examples also took decades, often required significant advocacy and political pressure, and still left major access gaps globally. And unlike antivirals, brain implants require surgical infrastructure and ongoing clinical management that pills do not. The comparison may not hold as well as the optimists assume.
The NeurotechMag piece How Neurotech Is Quietly Replacing Antidepressants for Some Patients maps how the non-invasive end of the spectrum — consumer headsets and wearables — is diffusing faster than implants. That’s genuinely encouraging. But non-invasive devices and invasive implants don’t cover the same ground. For the severest cases of treatment-resistant depression, paralysis, or Parkinson’s, only implants get close enough to make the difference.
Specific interventions that researchers and bioethicists have proposed include: ⚡
Mandatory access planning as part of FDA approval pathways for high-cost neural devices, requiring manufacturers to submit reimbursement strategies alongside efficacy data
Public funding for trial site expansion to underserved regions, not just major academic medical centers
Neural data as a public good framework, in which the data generated by implanted devices cannot be commodified or used as a commercial asset without explicit benefit-sharing with patients
International technology transfer mechanisms modeled on existing vaccine access programs, so that BCI technology developed in wealthy nations doesn’t simply bypass lower-income countries entirely
None of this is politically easy. Some of it is politically close to impossible in the current US environment. And the companies building these devices — funded by venture capital with specific return expectations — are not structurally aligned with equity goals unless regulatory frameworks create that alignment.
UNESCO itself has noted that if access to advanced neurotechnology is limited to the wealthy, it could further increase the gap between this social group and others at the international, national, or local level, and potentially lead to social tensions and conflict. That’s a careful way of saying something less careful: a world where some people’s brains are literally more capable than others because of money is a world with a new and unusually deep axis of inequality. Not metaphorically. Structurally.
So here’s the question worth sitting with: if we accept that brain implants will help some people dramatically, and we also accept that unmanaged markets will distribute them unequally, what exactly are we willing to do about it — and when? Because right now, the technology is moving faster than the policy, and the window for getting the structural choices right is open but not indefinitely.